Cargando…

Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases

The ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD)) protein is an scaffold component of different inflammasomes, intracellular multiprotein platforms of the innate immune system that are activated in response to pathogens or intracellular damage. The form...

Descripción completa

Detalles Bibliográficos
Autores principales: Soriano-Teruel, Paula M., García‑Laínez, Guillermo, Marco-Salvador, María, Pardo, Julián, Arias, Maykel, DeFord, Christian, Merfort, Irmgard, Vicent, María J., Pelegrín, Pablo, Sancho, Mónica, Orzáez, Mar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667020/
https://www.ncbi.nlm.nih.gov/pubmed/34903717
http://dx.doi.org/10.1038/s41419-021-04420-1
_version_ 1784614315629740032
author Soriano-Teruel, Paula M.
García‑Laínez, Guillermo
Marco-Salvador, María
Pardo, Julián
Arias, Maykel
DeFord, Christian
Merfort, Irmgard
Vicent, María J.
Pelegrín, Pablo
Sancho, Mónica
Orzáez, Mar
author_facet Soriano-Teruel, Paula M.
García‑Laínez, Guillermo
Marco-Salvador, María
Pardo, Julián
Arias, Maykel
DeFord, Christian
Merfort, Irmgard
Vicent, María J.
Pelegrín, Pablo
Sancho, Mónica
Orzáez, Mar
author_sort Soriano-Teruel, Paula M.
collection PubMed
description The ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD)) protein is an scaffold component of different inflammasomes, intracellular multiprotein platforms of the innate immune system that are activated in response to pathogens or intracellular damage. The formation of ASC specks, initiated by different inflammasome receptors, promotes the recruitment and activation of procaspase-1, thereby triggering pyroptotic inflammatory cell death and pro-inflammatory cytokine release. Here we describe MM01 as the first-in-class small-molecule inhibitor of ASC that interferes with ASC speck formation. MM01 inhibition of ASC oligomerization prevents activation of procaspase-1 in vitro and inhibits the activation of different ASC-dependent inflammasomes in cell lines and primary cultures. Furthermore, MM01 inhibits inflammation in vivo in a mouse model of inflammasome-induced peritonitis. Overall, we highlight MM01 as a novel broad-spectrum inflammasome inhibitor for the potential treatment of multifactorial diseases involving the dysregulation of multiple inflammasomes.
format Online
Article
Text
id pubmed-8667020
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86670202021-12-14 Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases Soriano-Teruel, Paula M. García‑Laínez, Guillermo Marco-Salvador, María Pardo, Julián Arias, Maykel DeFord, Christian Merfort, Irmgard Vicent, María J. Pelegrín, Pablo Sancho, Mónica Orzáez, Mar Cell Death Dis Article The ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD)) protein is an scaffold component of different inflammasomes, intracellular multiprotein platforms of the innate immune system that are activated in response to pathogens or intracellular damage. The formation of ASC specks, initiated by different inflammasome receptors, promotes the recruitment and activation of procaspase-1, thereby triggering pyroptotic inflammatory cell death and pro-inflammatory cytokine release. Here we describe MM01 as the first-in-class small-molecule inhibitor of ASC that interferes with ASC speck formation. MM01 inhibition of ASC oligomerization prevents activation of procaspase-1 in vitro and inhibits the activation of different ASC-dependent inflammasomes in cell lines and primary cultures. Furthermore, MM01 inhibits inflammation in vivo in a mouse model of inflammasome-induced peritonitis. Overall, we highlight MM01 as a novel broad-spectrum inflammasome inhibitor for the potential treatment of multifactorial diseases involving the dysregulation of multiple inflammasomes. Nature Publishing Group UK 2021-12-13 /pmc/articles/PMC8667020/ /pubmed/34903717 http://dx.doi.org/10.1038/s41419-021-04420-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Soriano-Teruel, Paula M.
García‑Laínez, Guillermo
Marco-Salvador, María
Pardo, Julián
Arias, Maykel
DeFord, Christian
Merfort, Irmgard
Vicent, María J.
Pelegrín, Pablo
Sancho, Mónica
Orzáez, Mar
Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases
title Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases
title_full Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases
title_fullStr Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases
title_full_unstemmed Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases
title_short Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases
title_sort identification of an asc oligomerization inhibitor for the treatment of inflammatory diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667020/
https://www.ncbi.nlm.nih.gov/pubmed/34903717
http://dx.doi.org/10.1038/s41419-021-04420-1
work_keys_str_mv AT sorianoteruelpaulam identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT garcialainezguillermo identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT marcosalvadormaria identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT pardojulian identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT ariasmaykel identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT defordchristian identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT merfortirmgard identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT vicentmariaj identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT pelegrinpablo identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT sanchomonica identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases
AT orzaezmar identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases